« Return to News | CROs/Service Providers

Phase Forward Agrees to $10M Acquisition, Multi-Year Partnership with Covance

Wednesday, July 15, 2009 01:30 PM

Covance is selling its interactive voice and web response services (IVR/IWR) business to eClinical provider Phase Forward for $10 million cash, and the two companies have entered into a multi-year agreement making Phase Forward a preferred provider for the contract research organization (CRO).

Under the terms of the agreement, Phase Forward will provide electronic data capture (EDC) and IVR/IWR services to Covance clients for the next five years. The two companies expect to close the acquisition by the end of August. 

Phase Forward and Covance will also collaborate on the development of future technologies to be used in clinical trials, including EDC, bedside data capture and electronic diaries, with the intent of improving the efficiency of drug development.

"Covance and Phase Forward are committed to working together to deliver best-of-class solutions to our clinical trial customers," said Phase Forward chairman and CEO Bob Weiler in a statement. "Covance has been a pioneering leader in the IVRS/ IWRS market and we look forward to building upon their success. We are also pleased to solidify our long-term strategic relationship with one of the world's leading and most successful CROs."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.